Urology Today.net

Site updated at Thursday, 12 May 2016

Common Urological Problems

Chemotherapy

J&J drug offers hope in advanced prostate cancer

Men with advanced prostate cancer lived nearly four months longer on a new pill from Johnson & Johnson, according to keenly awaited study data that researchers said would change clinical practice.

Abiraterone, which could reach the market next year, provides a new option for men with an aggressive type of prostate cancer.

Its… J&J drug offers hope in advanced prostate cancer   



Men’s Health Update Covers New BPH, Prostate Cancer Treatments

CHARLOTTESVILLE, VA (February 22, 2011) - The Focused Ultrasound Surgery Foundation has released a special men’s heath update in its February 2011 online newsletter.

According to the update, tremendous progress being made in developing new minimally-invasive and highly precise treatments for two conditions that afflict millions of men worldwide - prostate cancer and benign… Men’s Health Update Covers New BPH, Prostate Cancer Treatments   



Antifungal drug delays need for chemo in advanced prostate cancer

The oral antifungal drug itraconazole, most commonly used to treat nail fungus, may keep prostate cancer from worsening and delay the need for chemotherapy in men with advanced disease. Details of the finding, from a clinical trial led by Johns Hopkins experts, are scheduled for presentation on Saturday, June 4 at the 2011 American… Antifungal drug delays need for chemo in advanced prostate cancer   



New treatment option for advanced prostate cancer

Prostate cancer that has become resistant to hormone treatment and that does not respond to radiation or chemotherapy requires new methods of treatment. By attacking stem cell-like cells in prostate cancer, researchers at Lund University are working on a project to develop a new treatment option.

A successful interdisciplinary project is underway between two… New treatment option for advanced prostate cancer   



J&J’s prostate cancer drug approved in EU

Johnson & Johnson’s prostate cancer drug Zytiga has been approved in the European Union, paving the way for the launch of a new treatment for men whose disease has progressed after chemotherapy, the company said on Wednesday.

The decision was expected after European regulators endorsed the treatment in July. J&J’s Janssen unit has European… J&J’s prostate cancer drug approved in EU   



Zytiga, Prostate Cancer Drug, Improves Survival: Study

Johnson & Johnson’s drug for advanced prostate cancer, Zytiga, was deemed so beneficial in patients who had not received chemotherapy that safety advisors said those in the placebo group of a late stage trial should be offered the treatment, the company said

The unanimous recommendation by independent safety monitors was based on improvements in… Zytiga, Prostate Cancer Drug, Improves Survival: Study   



For advanced prostate cancer, new drug slows disease

A new medication proved effective in slowing the spread of metastatic prostate cancer, while helping to maintain the quality of life, in patients with advanced disease. The phase 3 study was unblinded midway, allowing patients receiving the placebo to instead take the drug because of the favorable results.

The study is the first randomized… For advanced prostate cancer, new drug slows disease   



Drug slows advanced prostate cancer: study

A drug that is already approved for prostate cancer has been shown to slow the spread of advanced forms of the disease for the first time, according to research released Saturday.

Zytiga, made by Johnson and Johnson, is being tested in a randomized phase III trial involving 1,088 men with prostate cancer at 151… Drug slows advanced prostate cancer: study   



Gold Nanoparticle Prostate Cancer Treatment Found Safe in Dogs, MU Study Shows

Currently, large doses of chemotherapy are required when treating certain forms of cancer, resulting in toxic side effects. The chemicals enter the body and work to destroy or shrink the tumor, but also harm vital organs and drastically affect bodily functions. Now, scientists at the University of Missouri have proven that a new form… Gold Nanoparticle Prostate Cancer Treatment Found Safe in Dogs, MU Study Shows   



Bristol’s Yervoy falls short in prostate cancer study

Bristol-Myers Squibb Co’s immunotherapy drug Yervoy failed to significantly prolong survival among patients with advanced prostate cancer who had previously received chemotherapy, according to limited data from the first late-stage study of the drug for the condition.

Yervoy (ipilimumab) frees the immune system to attack and kill cancer cells by blocking the action of… Bristol’s Yervoy falls short in prostate cancer study   



Genetic profile predicts which bladder cancer patients will benefit from early chemotherapy

Three genetic changes can predict whether a patient will benefit from chemotherapy before surgery to remove bladder cancer, according to new findings presented by Fox Chase Cancer Center researchers during the 50th Annual Meeting of the American Society of Clinical Oncology.

During the study, 36 patients with muscle-invasive bladder cancer received chemotherapy before surgery,… Genetic profile predicts which bladder cancer patients will benefit from early chemotherapy   



Two major studies strengthen case for prostate cancer drug before chemotherapy

Pioneering prostate cancer drug abiraterone significantly extends the lives of men with advanced prostate cancer if given before chemotherapy, the results of a major phase III clinical trial have shown.

The results, published in Lancet Oncology, showed that men with advanced, aggressive prostate cancer lived more than four months longer on average if they… Two major studies strengthen case for prostate cancer drug before chemotherapy   



calcifications in the blood vessels1 - american journal of epidemiology1 - diets1 - urethral pain1 - desire or erection1 - clinical journal of the american society nephrology3 - kidney function18 - early kidney damage1 - laser light1 - glutamine1 - bladder control4 - early-stage cancer1 - vitamin supplements1 - recurrent bladder infection1 - hemolytic uremic syndrome1 - prostate cancer cells2 - aggregated disease groups1 - kidney problems2 - renal function2 - recurrent tumors1 - dietary magnesium3 - abiraterone2 - renal tumors1 - recurrent incontinence1 - lithium1 - nephrin1 - pelvic diaphragm1 - ralp1 - peritonitis1 - hormone-deprivation therapy1 -